Group 1 - Daxing District is committed to developing the biopharmaceutical industry as a core track for high-quality development, aiming to enhance its international competitiveness in the cell and gene therapy (CGT) field [1][2] - The OpenCGT platform, launched by Jitai Technology, focuses on addressing industry pain points in precise drug delivery, reducing development barriers and costs, and facilitating the research and clinical transformation of breakthrough CGT therapies [1][2] - Jitai Technology has completed a Series D financing round, raising a total of 400 million RMB, which will accelerate the advancement of multiple strategic priorities, including platform automation upgrades and international strategic cooperation [2][3] Group 2 - The Beijing Municipal Science and Technology Commission and other departments have announced a three-year action plan to accelerate innovation in the CGT industry, aiming to cultivate over 20 leading technology companies in the field by 2027 [2] - The Beijing Pharmaceutical Health Industry Investment Fund, established by the Beijing government, focuses on investing in innovative drugs, medical devices, and emerging industries such as CGT and digital healthcare [3] - The OpenCGT platform fills a critical gap in the transformation of high-end formulations and delivery systems, significantly contributing to Beijing's goal of becoming an international innovation hub for the CGT industry [3]
剂泰科技AI破局纳米递送 赋能北京生物医药产业新引擎
Zhong Guo Jing Ji Wang·2025-08-07 06:20